Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp. (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany. The IM Cannabis news feed on Stock Titan aggregates company-issued press releases and other coverage related to its operations, strategy, governance, and capital markets activity.
Readers can expect frequent corporate updates, such as board and management changes, including appointments and departures of directors and executive officers. These announcements often detail the backgrounds of new appointees and outline how governance changes fit within the company’s broader strategic review.
The news stream also features financial reporting items, including notices about upcoming earnings releases and press releases summarizing interim financial results. These communications may discuss revenue trends, gross margin, non-IFRS measures such as Adjusted EBITDA, and commentary on factors affecting performance in Israel and Germany.
Another key category of coverage involves strategic and transactional developments. IM Cannabis has reported on initiatives to identify additional business opportunities, the signing of a non-binding term sheet to acquire a majority stake in a quantum computing bio data company, and its evaluation of potential expansion into the United States cannabis market, as well as possible divestitures of its German and Israeli operations. Capital markets updates, such as warrant amendments, resale registration statements, and Nasdaq listing compliance notices, are also part of the company’s news flow.
For investors and observers tracking IMCC, this page offers a centralized view of how the company communicates its progress in medical cannabis markets, its strategic review, and its responses to regulatory and market conditions. Users who follow IM Cannabis can use this news feed to monitor developments over time and review the company’s own descriptions of its plans and performance.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) announced the first closing of its acquisition of Panaxia Pharmaceutical Industries, enhancing its online pharmacy and distribution capabilities in Israel. This strategic move is expected to boost IMC's market presence and operational efficiency. Additionally, the company launched its WAGNERS brand in Canada with new product offerings and achieved significant cultivation milestones, harvesting 8,000 plants in May 2021. IMC also completed a successful run-off of its loan portfolio, realizing a 24% internal rate of return.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) reported Q1 2021 revenues of $8.8 million, up 80% sequentially from Q4 2020 and up 554% year-over-year. The gross margin reached 53%. The revenue increase was driven by growth in Israel, Germany, and Canada, aided by the successful integration of Trichome. Adjusted EBITDA loss was $969,000, but would have been a profit of $799,000/b) without acquisition costs. The company anticipates Q2 2021 revenues of
IM Cannabis Corp. has successfully closed an overnight marketed offering, raising approximately US$35 million by selling 6,086,956 common shares at US$5.75 each. Alongside the shares, the company issued 3,043,478 warrants at an exercise price of US$7.20 for a term of 5 years. The proceeds will support growth in Israel, Germany, and Canada, facilitate strategic mergers and acquisitions, and provide general working capital. The offering was conducted under the company's effective registration statement, with co-lead agents from A.G.P./Alliance Global Partners and Roth Capital Partners.
IM Cannabis Corp. (IMCC) has announced an overnight marketed offering to raise approximately US$35 million through the sale of up to 6,086,956 common shares at US$5.75 each and 3,043,478 warrants. The company plans to use the proceeds for growth initiatives in Israel, Germany, and Canada, along with strategic mergers and acquisitions. The offering is expected to close around May 7, 2021, subject to customary conditions. Key agents involved include A.G.P./Alliance Global Partners and Roth Capital Partners.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) has announced an overnight marketed offering of common shares on a best-efforts basis. The Offering may include purchase warrants for additional share purchases. Agents A.G.P./Alliance Global Partners and Roth Capital Partners will lead the Offering, also featuring a 30-day Over-Allotment Option for additional securities. Funds raised will support growth in core markets (Israel, Germany, Canada), strategic acquisitions, and working capital needs. The Offering is subject to customary conditions and relies on an effective shelf registration statement.
IM Cannabis Corp. (CSE:IMCC)(NASDAQ:IMCC) has entered into a definitive agreement to acquire Panaxia Pharmaceutical Industries Israel Ltd. for $7.2 million. This acquisition will enhance IMC's patient offerings in Israel and strengthen direct relationships with customers. The deal will expand IMC's online pharmacy services, allowing access to a broad range of medical cannabis products. The transaction includes a two-stage closing process with regulatory approval expected by July 30, 2021. The combination is anticipated to provide significant revenue opportunities and synergies with IMC's Canadian production portfolio.
IM Cannabis Corp. (CSE:IMCC) reported Q4 2020 revenues of $4.9 million with a gross margin of 57%. For FY 2020, revenues reached $15.9 million, a 75% increase from 2019. Preliminary Q1 2021 revenues are expected between $8.5 to $9.0 million. Q2 2021 outlook anticipates $17 to $19 million due to growth in Israel and Germany, and contributions from the acquisition of Trichome Financial Corp. Net losses for FY 2020 were approximately $28.7 million, driven by revaluation of warrants and operational costs. The company also proposed an acquisition of MYM Nutraceuticals, expected to complete by Q2 2021.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) announced a new supply agreement involving its subsidiary, Adjupharm, and Northern Green Canada (NGC), enhancing its product offerings in the German medical cannabis market. This partnership strengthens Adjupharm's distribution capabilities across over 6,000 pharmacies. The deal positions IMC for increased growth as NGC, a EU GMP-certified producer, provides high-quality medical cannabis. Additionally, IMC disclosed the termination of a purchase agreement with Zur Rose Pharma effective March 30, 2021.
IM Cannabis Corp. (NASDAQ: IMCC) has announced its acquisition of MYM Nutraceuticals Inc. and its subsidiary Highland Grow Inc. This deal is projected to enhance IMC's position in the premium cannabis market, with Highland Grow expected to contribute $29 million to $38 million in net revenue in 2021 and 2022. The purchase price values Highland Grow at 2.3x net revenue and 6.7x EBITDA. The transaction is anticipated to be immediately accretive and will provide significant distribution synergies and enhanced product offerings.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) has filed a final short form base shelf prospectus with Canadian securities authorities and a corresponding registration statement with the SEC. This will permit the Company to offer up to US$250 million in securities over a 25-month period. Proceeds may be utilized for corporate purposes, capital expenditures, and acquisitions. The shelf prospectus also allows for 'at-the-market' distributions via the CSE and NASDAQ. Copies of the prospectus are available on SEDAR and EDGAR.